← Human Trials & Peer-Reviewed Studies
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
Plain-language guide to PMID 31707465 (2020): open-label randomized controlled trial study of Teriparatide.
Key Facts
- PMID
- 31707465
- Journal
- Journal of bone and mineral metabolism
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Takada J et al. (9 authors)
- DOI
- 10.1007/s00774-019-01057-1
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide, published as a randomized controlled trial.
Procollagen type I N-terminal propeptide (P1NP), a bone formation marker, reportedly predicts bone mineral density (BMD) response to teriparatide treatment in treatment-naive patients with osteoporosis.
This post hoc analysis investigated the comparative utility of early changes in P1NP in predicting BMD response in patients who participated in the STRUCTURE trial, which enrolled patients who switched treatment from bisphosphonates to romosozumab/teriparatide.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.
How the Study Was Run
The researchers set it up as a randomized and open-label study.
Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Teriparatide study did not mask who received what.
BMD was assessed by dual-energy X-ray absorptiometry at the proximal femur and lumbar spine (LS) at baseline and months 6 and 12.
What Was Measured
PubMed files the paper under topics including Alendronate, Antibodies, Monoclonal, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling and Peptide Fragments.
The authors tagged it with the keywords Bisphosphonates, Osteoporosis, P1NP, Romosozumab and Teriparatide.
What This Means in Plain Language
The paper is a randomized and open-label study of Teriparatide.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2020 (Journal of bone and mineral metabolism), a journal based in Japan.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.